Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 24, 2026, 5:34 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 5,477 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Lung Cancer Diagnosis Clear all
Recruiting Phase 1Phase 2 Interventional

A Beta-only IL-2 ImmunoTherapY Study

NCT05086692
View directory record Official record
Conditions
Advanced Solid Tumor, Unresectable Solid Tumor, Clear Cell Renal Cell Carcinoma, Triple Negative Breast Cancer, Non-Small Cell Lung Cancer Squamous, Non-Small Cell Lung Cancer Non-squamous, Colorectal Cancer (MSI-H), Gastric Cancer, Cervical Cancer, Basal Cell Carcinoma, Bladder Cancer, Merkel Cell Carcinoma, Squamous Cell Carcinoma of Head and Neck, Cutaneous Squamous Cell Carcinoma, Pleural Mesothelioma, Esophageal Cancer, Endometrial Carcinoma, Solid Tumor, Solid Tumor, Adult, MSI-H Solid Malignant Tumor, Cancer With A High Tumor Mutational Burden, Epithelial Ovarian Carcinoma, Primary Peritoneal Cancer, Gastroesophageal Junction (GEJ) Cancer, Acral Melanoma, Mucosal Melanoma, Cutaneous Melanoma, DMMR Solid Malignant Tumor, Fallopian Tube Cancer, Ovarian Cancer, MSI-H Cancer, DMMR Cancer, Pancreas Adenocarcinoma (MSI-H), Skin Cancer, Viral Cancer, Cervical Cancers, Endometrial Cancer
Interventions
MDNA11, Pembrolizumab (KEYTRUDA®)
Drug
Lead sponsor
Medicenna Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
7
States / cities
San Diego, California • San Francisco, California • Santa Monica, California + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2025 · Synced Sep 24, 2026, 5:34 AM EDT
Not yet recruiting Phase 2 Interventional

GCC 2545- Improving Post-Radiotherapy Respiratory Function Through Sparing Serial and Parallel Components in the Lung

NCT07679607
View directory record Official record
Conditions
Lung Cancer (NSCLC), Radiation
Interventions
SOC Radiation Treatment Planning, INSPIRE Radiation Treatment Planning
Radiation
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Sep 24, 2026, 5:34 AM EDT
Recruiting No phase listed Observational

Assess Diversity of Gut Microbiome in Met NSCLC in Correlation to Tx & Adverse Effects

NCT06221800
View directory record Official record
Conditions
Non Small Cell Lung Cancer
Interventions
Microbiome
Diagnostic Test
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Feb 4, 2026 · Synced Sep 24, 2026, 5:34 AM EDT
Completed Phase 1 Interventional

Azacitidine in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer

NCT02009436
View directory record Official record
Conditions
Recurrent Non-Small Cell Lung Carcinoma, Stage IV Non-Small Cell Lung Cancer
Interventions
Azacitidine, Laboratory Biomarker Analysis, Pharmacological Study
Drug · Other
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Feb 6, 2020 · Synced Sep 24, 2026, 5:34 AM EDT
Withdrawn Phase 3 Interventional

A Safety Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Non-small Cell Lung Cancer

NCT03048136
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
Nivolumab, Ipilimumab
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
9
States / cities
San Francisco, California • Lincoln, Nebraska • Hackensack, New Jersey + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2018 · Synced Sep 24, 2026, 5:34 AM EDT
Completed Phase 2 Interventional Results available

Acetylsalicylic Acid Compared to Placebo in Treating High-Risk Patients With Subsolid Lung Nodules

NCT02169271
View directory record Official record
Conditions
Current Smoker, Former Smoker, Multiple Pulmonary Nodules, Tobacco Use Disorder
Interventions
Aspirin, Laboratory Biomarker Analysis, Placebo
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
50 Years and older
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 20, 2020 · Synced Sep 24, 2026, 5:34 AM EDT
Completed Phase 2 Interventional Results available

A Study of Pemetrexed and Carboplatin/Cisplatin or Gemcitabine and Carboplatin/Cisplatin With or Without IMC-1121B in Participants Previously Untreated With Recurrent or Advanced Non-Small Cell Lung Cancer (NSCLC)

NCT01160744
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
IMC-1121B (ramucirumab), Pemetrexed, Carboplatin (AUC 6), Cisplatin, Gemcitabine, Carboplatin (AUC 5)
Biological · Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
38
States / cities
Scottsdale, Arizona • Tucson, Arizona • Corona, California + 35 more
Source: ClinicalTrials.gov public record
Updated Sep 12, 2019 · Synced Sep 24, 2026, 5:34 AM EDT
No Longer Available No phase listed Expanded access

Expanded Treatment Protocol With LDK378 in ALK(+) NSCLC

NCT01947608
View directory record Official record
Conditions
Non-small Cell Lung Cancer (NSCLC)
Interventions
LDK378
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
27
States / cities
Chandler, Arizona • Gilbert, Arizona • Goodyear, Arizona + 23 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2020 · Synced Sep 24, 2026, 5:34 AM EDT
Terminated Phase 2 Interventional

Trial of Pemetrexed With or Without PF-3512676 in Advanced Non-Small Cell Lung Cancer

NCT00321308
View directory record Official record
Conditions
Carcinoma, Non-Small Cell Lung
Interventions
pemetrexed, pemetrexed + PF-3512676
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
17
States / cities
Litchfield Park, Arizona • Sun City, Arizona • Bentonville, Arkansas + 12 more
Source: ClinicalTrials.gov public record
Updated Sep 27, 2009 · Synced Sep 24, 2026, 5:34 AM EDT
Terminated Phase 2 Interventional Results available

Sorafenib With Capecitabine for Patients With Measurable Hepatocellular Carcinoma

NCT01032850
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
Sorafenib & Capecitabine
Drug
Lead sponsor
New Mexico Cancer Research Alliance
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
3
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Jun 1, 2021 · Synced Sep 24, 2026, 5:34 AM EDT
Completed Phase 2 Interventional Results available

BATTLE Program: ZD6474 in Previously Treated Subjects With NSCLC

NCT00410189
View directory record Official record
Conditions
Lung Cancer
Interventions
ZD6474
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 22, 2015 · Synced Sep 24, 2026, 5:34 AM EDT
Recruiting Phase 1Phase 2 Interventional

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

NCT04585750
View directory record Official record
Conditions
Advanced Solid Tumor, Advanced Malignant Neoplasm, Metastatic Cancer, Metastatic Solid Tumor, Lung Cancer, Ovarian Cancer, Endometrial Cancer, Prostate Cancer, Colorectal Cancer, Breast Cancer, Other Cancer, Locally Advanced, Head and Neck Cancer, Gall Bladder Cancer, Small Cell Lung Cancer, Small Cell Lung Cancer ( SCLC ), Small Cell Lung Carcinoma, NSCLC, NSCLC (Non-small Cell Lung Cancer), SCLC, Non-Small Cell Lung Carcinoma, Triple Negative Breast Cancer, TNBC, HER2+ Breast Cancer, Non-Small Cell Lung Cancer, ER/PR Positive Breast Cancer, HER2- Breast Cancer, HER2-positive Breast Cancer, HER2-negative Breast Cancer, ER/PR(+), Her2(-) Breast Cancer
Interventions
rezatapopt, pembrolizumab
Drug
Lead sponsor
PMV Pharmaceuticals, Inc
Industry
Eligibility
12 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
33
States / cities
Irvine, California • La Jolla, California • Los Angeles, California + 27 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Sep 24, 2026, 5:34 AM EDT
Terminated Phase 1 Interventional

A Study to Investigate LYL845 in Adults With Solid Tumors

NCT05573035
View directory record Official record
Conditions
Melanoma, Non-small Cell Lung Cancer, Colorectal Cancer
Interventions
LYL845
Biological
Lead sponsor
Lyell Immunopharma, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
18
States / cities
Sacramento, California • Santa Monica, California • Stanford, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2025 · Synced Sep 24, 2026, 5:34 AM EDT
Recruiting Not applicable Interventional

Dental Cleaning to Prevent Chronic Graft-Versus-Host Disease

NCT07535008
View directory record Official record
Conditions
Chronic Graft Versus Host Disease, Acute Graft Versus Host Disease, Hematopoietic and Lymphatic System Neoplasm
Interventions
Dental Cleaning, Dental Plaque sampling
Procedure
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Sep 24, 2026, 5:34 AM EDT
Recruiting Phase 1 Interventional

Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including Mesothelioma

NCT06885697
View directory record Official record
Conditions
Mesothelioma, Neoplasms, Stomach Neoplasms, Pancreatic Neoplasms, Ovarian Neoplasms, Lung Neoplasms, Thymus Neoplasms, Colonic Neoplasms
Interventions
cyclophosphamide, fludarabine, TNhYP218 CAR T Cells, mesothelin expression testing
Drug · Biological · Device
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2044
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Sep 24, 2026, 5:34 AM EDT
Active, not recruiting Phase 2 Interventional

Determining Whether Durvalumab in Combination With Radiation Therapy Can Prevent the Progression of Non-Small Cell Lung Cancer

NCT03999710
View directory record Official record
Conditions
Non Small Cell Lung Cancer, Lung Cancer, Nsclc, NSCLC Stage II, NSCLC, Stage III
Interventions
Radiation Therapy, Durvalumab
Radiation · Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
9
States / cities
Miami, Florida • Basking Ridge, New Jersey • Middletown, New Jersey + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 4, 2026 · Synced Sep 24, 2026, 5:34 AM EDT
Completed No phase listed Observational

Identification of Serum Markers For Tumor Hypoxia in Non-Small Cell Lung Cancers

NCT00185913
View directory record Official record
Conditions
Lung Cancer
Interventions
Not listed
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2008
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Apr 21, 2010 · Synced Sep 24, 2026, 5:34 AM EDT
Completed Phase 2 Interventional

A Study of NK012 in Patients With Relapsed Small Cell Lung Cancer

NCT00951613
View directory record Official record
Conditions
Small Cell Lung Cancer
Interventions
NK012
Drug
Lead sponsor
Nippon Kayaku Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 19, 2013 · Synced Sep 24, 2026, 5:34 AM EDT
Active, not recruiting Phase 2 Interventional Results available

A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors

NCT02498613
View directory record Official record
Conditions
Advanced Malignant Solid Neoplasm, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Lung Small Cell Carcinoma, Metastatic Pancreatic Adenocarcinoma, Metastatic Triple-Negative Breast Carcinoma, Pancreatic Ductal Adenocarcinoma, Stage III Breast Cancer AJCC v7, Stage III Lung Non-Small Cell Cancer AJCC v7, Stage III Lung Small Cell Carcinoma AJCC v7, Stage III Pancreatic Cancer AJCC v6 and v7, Stage IIIA Breast Cancer AJCC v7, Stage IIIA Lung Non-Small Cell Cancer AJCC v7, Stage IIIA Lung Small Cell Carcinoma AJCC v7, Stage IIIB Breast Cancer AJCC v7, Stage IIIB Lung Non-Small Cell Cancer AJCC v7, Stage IIIB Lung Small Cell Carcinoma AJCC v7, Stage IIIC Breast Cancer AJCC v7, Stage IV Breast Cancer AJCC v6 and v7, Stage IV Lung Non-Small Cell Cancer AJCC v7, Stage IV Lung Small Cell Carcinoma AJCC v7, Stage IV Pancreatic Cancer AJCC v6 and v7, Triple-Negative Breast Carcinoma, Unresectable Lung Small Cell Carcinoma, Unresectable Pancreatic Adenocarcinoma, Unresectable Pancreatic Carcinoma, Unresectable Triple-Negative Breast Carcinoma
Interventions
18F-Fluoromisonidazole, Cediranib Maleate, Laboratory Biomarker Analysis, Olaparib, Positron Emission Tomography
Other · Drug · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
14
States / cities
La Jolla, California • Sacramento, California • San Diego, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Sep 24, 2026, 5:34 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Study of DM005 in Patients With Advanced Solid Tumors

NCT06515990
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung, Squamous Cell Carcinoma of Head and Neck, Solid Carcinoma
Interventions
DM005
Drug
Lead sponsor
Doma Biopharmaceutical（Suzhou）Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
208 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
3
States / cities
Detroit, Michigan • Dallas, Texas • Fairfax, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Sep 24, 2026, 5:34 AM EDT
Active, not recruiting Phase 2 Interventional

Study of Sacituzumab Govitecan Combinations in First-line Treatment of Participants With Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC)

NCT05186974
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
Sacituzumab Govitecan-hziy (SG), Pembrolizumab, Carboplatin, Cisplatin
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
193 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
22
States / cities
Anchorage, Alaska • Beverly Hills, California • Los Angeles, California + 17 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Sep 24, 2026, 5:34 AM EDT
Active, not recruiting Phase 3 Interventional

ONC-392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 Inhibitors

NCT05671510
View directory record Official record
Conditions
Non Small Cell Lung Cancer
Interventions
Gotistobart, Docetaxel
Drug
Lead sponsor
OncoC4, Inc.
Industry
Eligibility
18 Years and older
Enrollment
630 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
46
States / cities
Dothan, Alabama • Russellville, Arkansas • Cerritos, California + 42 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Sep 24, 2026, 5:34 AM EDT
Recruiting No phase listed Observational

Interprofessional Pharmacogenomics (IPGx) Registry and Repository

NCT06726590
View directory record Official record
Conditions
Diabetes, Cholesterol, Cancer, Blood Pressure Disorders, Heart Disease, Respiratory Ilness, COPD, Adverse Drug Reaction (ADR), Poly Pharmacy
Interventions
Not listed
Lead sponsor
Texas A&M University
Other
Eligibility
18 Years and older
Enrollment
3,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Bryan, Texas
Source: ClinicalTrials.gov public record
Updated Sep 11, 2025 · Synced Sep 24, 2026, 5:34 AM EDT
Completed Phase 1 Interventional

Specialized Radiation Therapy in Treating Patients With Stage II, Stage III, Stage IV, or Recurrent Non-Small Cell Lung Cancer and Poor Performance Status

NCT00986297
View directory record Official record
Conditions
Lung Cancer
Interventions
hypofractionated radiation therapy
Radiation
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 120 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
2
States / cities
Stanford, California • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 19, 2020 · Synced Sep 24, 2026, 5:34 AM EDT